CHINA PHARMA HOLDINGS, INC. 8-K

What Happened

• China Pharma Holdings, Inc. (through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd.) announced in an 8-K filed March 3, 2026 that on February 26, 2026 it entered a Technology Transfer Agreement with Xiaoyan Zhang to acquire an invention patent titled "Prinsepia Utilis Esterol Sublingual Tablets and Method for Its Preparation."
• The agreed transfer price is $6.93 million, to be paid in the Company’s common stock at $0.55 per share (par value $0.001). The transferor (or a designated third party) will also provide technical services such as product R&D, preparation of registration materials, and registration applications.

Key Details

• Agreement signing date: February 26, 2026; 8-K filed: March 3, 2026.
• Purchase price: $6.93 million, payable in stock at $0.55/share → 12,600,000 shares to be issued.
• Target asset: patent for Prinsepia Utilis Esterol Sublingual Tablets and the preparation method.
• Related SEC disclosures: Item 1.01 (material agreement) and Item 3.02 (unregistered sale of equity securities).

Why It Matters

• The transaction gives China Pharma an owned patent for a sublingual tablet formulation that could expand its product pipeline if developed and approved; the transferor will assist with R&D and regulatory work, which can help advance commercialization.
• Paying with stock conserves cash but will dilute existing shareholders by roughly 12.6 million new shares. The issuance is reported as an unregistered sale, which can affect resale restrictions.
• This is a material deal (entered into by a subsidiary) but is not a report of revenues or earnings; investors should watch for subsequent regulatory filings, development milestones, or further details on the stock issuance and commercialization plan.